Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Mar 1;38(3):339-349.
doi: 10.1097/QAD.0000000000003763. Epub 2023 Oct 19.

Dynamic choice HIV prevention intervention at outpatient departments in rural Kenya and Uganda

Catherine A Koss  1 , James Ayieko  2 , Jane Kabami  3 , Laura B Balzer  4 , Elijah Kakande  3 , Helen Sunday  3 , Marilyn Nyabuti  2 , Erick Wafula  5 , Starley B Shade  1 , Edith Biira  3 , Fred Opel  2 , Hellen N Atuhaire  3 , Hideaki Okochi  1 , Sabina Ogachi  2 , Monica Gandhi  1 , Melanie C Bacon  6 , Elizabeth A Bukusi  2 , Gabriel Chamie  1 , Maya L Petersen  4 , Moses R Kamya  7 , Diane V Havlir  1 ; SEARCH study team
Affiliations
Clinical Trial

Dynamic choice HIV prevention intervention at outpatient departments in rural Kenya and Uganda

Catherine A Koss et al. AIDS. .

Abstract

Objective: HIV prevention service delivery models that offer product choices, and the option to change preferences over time, may increase prevention coverage. Outpatient departments in sub-Saharan Africa diagnose a high proportion of new HIV infections, but are an understudied entry point to biomedical prevention.

Design: Individually randomized trial of dynamic choice HIV prevention (DCP) intervention vs. standard-of-care (SOC) among individuals with current/anticipated HIV exposure risk at outpatient departments in rural Kenya and Uganda (SEARCH; NCT04810650).

Methods: Our DCP intervention included 1) product choice (oral preexposure prophylaxis [PrEP] or postexposure prophylaxis [PEP]) with an option to switch over time, 2) HIV provider- or self-testing, 3) service location choice (community vs. clinic-based), and 4) provider training on patient-centered care. Primary outcome was proportion of follow-up covered by PrEP/PEP over 48 weeks assessed via self-report.

Results: We enrolled 403 participants (61% women; median 27 years, IQR 22-37). In the DCP arm, 86% ever chose PrEP, 15% ever chose PEP over 48 weeks; selection of HIV self-testing increased from 26 to 51% and of out-of-facility visits from 8 to 52%. Among 376 of 403 (93%) with outcomes ascertained, time covered by PrEP/PEP was higher in DCP (47.5%) vs. SOC (18.3%); difference = 29.2% (95% confidence interval: 22.7-35.7; P < 0.001). Effects were similar among women and men (28.2 and 31.0% higher coverage in DCP, respectively) and larger during periods of self-reported HIV risk (DCP 64.9% vs. SOC 26.3%; difference = 38.6%; 95% confidence interval: 31.0-46.2; P < 0.001).

Conclusion: A dynamic choice HIV prevention intervention resulted in two-fold greater time covered by biomedical prevention products compared to SOC in general outpatient departments in eastern Africa.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

CAK has received grant support paid to the University of California, San Francisco from Gilead Sciences. All other authors declare no competing interests.

Figures

Figure 1.
Figure 1.
CONSORT Diagram
Figure 2.
Figure 2.
Choice of HIV prevention product, HIV testing modality, and visit location in DCP intervention arm through week 48
Figure 3.
Figure 3.
Primary outcome: Proportion of follow-up time covered by PrEP or PEP, by arm
Figure 4.
Figure 4.
Heatmaps of self-reported PrEP/PEP use and HIV exposure risk over time in DCP intervention (a) and SOC (b) arms
See this image and copyright information in PMC

Comment in

References

    1. UNAIDS. The path that ends AIDS: 2023 UNAIDS Global AIDS Update. In. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2023.
    1. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 2022; 399(10337):1779–1789. - PMC - PubMed
    1. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med 2021; 385(7):595–608. - PMC - PubMed
    1. Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 2018; 5(11):e629–e637. - PubMed
    1. Buchbinder SP, Havlir DV. Getting to Zero San Francisco: A collective impact approach. J Acquir Immune Defic Syndr 2019; 82 Suppl 3:S176–S182. - PMC - PubMed

Publication types

Substances

Associated data